Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 12,520 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Insomnia Disorders
Interventions: Placebo, JNJ-42847922, 5 mg, JNJ-42847922, 10 mg, JNJ-42847922, 20 mg, Zolpidem; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 24
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 20 more

Conditions: Anesthesia, Surgical Procedures, Elective
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Loma Linda, California • Miami, Florida + 18 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK256073, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Anniston, Alabama • Miami, Florida • Miami Gardens, Florida + 1 more

Conditions: Age-Related Macular Degeneration
Interventions: Eculizumab, Saline; Drug
Lead sponsor: Philip J. Rosenfeld, MD, PhD; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 39 more

Conditions: Knee Osteoarthritis
Interventions: Lorecivivint, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 69 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Placebo (for Dupilumab); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 50 more

Conditions: Thymoma and Thymic Carcinoma
Interventions: octreotide acetate, prednisone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 24
States / cities: Palo Alto, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Large B-Cell Lymphoma
Interventions: Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 60
States / cities: Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more

Conditions: Chronic Heart Failure With Preserved Ejection Fraction
Interventions: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 29
States / cities: Beverly Hills, California • Carmichael, California • West Hills, California + 26 more

Conditions: Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions: Ampreloxetine; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Alzheimer Disease
Interventions: Donepezil, Vitamin E; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more

Conditions: Hidradenitis Suppurativa
Interventions: Cutimed Sorbact Hydroactive B wound dressing, Cutimed Siltect wound dressing, Sorbion Sana multi-star wound dressing; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Etravirine (ETR); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 6 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • The Bronx, New York

Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions: Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 106
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more

Conditions: GERD With Erosive Esophagitis
Interventions: AZD0865; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 77
States / cities: Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more

Conditions: Hyperkalemia
Interventions: Patiromer; Drug
Lead sponsor: Vifor Pharma, Inc.; Industry
Eligibility: 0 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Alzheimer Disease
Interventions: sabirnetug, Placebo; Drug
Lead sponsor: Acumen Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Carlsbad, California • Fullerton, California • Irvine, California + 40 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, PF-04950615 (RN316); Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more

Conditions: Cystic Fibrosis
Interventions: AZLI, Placebo to match AZLI, Tobramycin inhalation solution; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more

Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Interventions: larotrectinib(Vitrakvi, BAY2757556); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 33
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 28 more

Conditions: Femoral Artery Stenosis, Femoral Artery Occlusion, Restenosis
Interventions: Lutonix DCB, Standard Uncoated Balloon Angioplasty Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 20
States / cities: Fairhope, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 17 more

Conditions: Hyperhidrosis
Interventions: Vehicle, ANT-1207; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Hialeah, Florida • Miami, Florida • Pinellas Park, Florida + 16 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 42
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 37 more

Search by objective public record fields.

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

Pancreatic Cancer Early Detection Consortium

Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Memory Impairment Study (Mild Cognitive Impairment Study)

Wound Dressings for Hidradenitis Suppurativa

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects